VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
The Cleveland Clinic
Study ID
NCT00274794
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • filgrastim — BIOLOGICAL
    10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
  • rituximab — BIOLOGICAL
    375 mg/m2, IV, Once per week for 3 weeks.

Study Details

RATIONALE: Drugs used in chemotherapy, such as busulfan, etoposide, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituximab, or chemotherapy, such as etoposide, helps stem cells move from the bone marrow to the blood so they can be collected and stored until transplant. Giving etoposide and G-CSF together with rituximab before a peripheral stem cell transplant may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: This randomized clinical trial is studying how well giving etoposide and G-CSF with or without rituximab works in treating patients who are undergoing an autologous peripheral stem cell transplant for B-cell non-Hodgkin's lymphoma.

Key Dates

Start date
Feb 29, 2000
Status verified
Mar 2011
Primary completion
May 31, 2006
Completion
May 31, 2006

Study Design

Enrollment
55 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Other: Rituxan + Etoposide + G-CSF
  • Other: Etoposide + G-CSF

Primary Outcome Measure

Correlate CD34+ cell yields with the addition of rituximab [ Time Frame: At least two weeks prior to transplant ]

Locations (1)

FacilityCityStateZIPSite coordinators
Cleveland Clinic Taussig Cancer InstituteClevelandOhio44195-

Find similar trials in Cleveland, OH

Related Studies